BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27687692)

  • 1. T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome.
    Magnano L; Martínez A; Carreras J; Martínez-Trillos A; Giné E; Rovira J; Dlouhy I; Baumann T; Balagué O; Campo E; López-Guillermo A; Villamor N
    Leuk Lymphoma; 2017 Apr; 58(4):842-850. PubMed ID: 27687692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.
    Alonso-Álvarez S; Vidriales MB; Caballero MD; Blanco O; Puig N; Martin A; Peñarrubia MJ; Zato E; Galende J; Bárez A; Alcoceba M; Orfão A; González M; García-Sanz R
    Leuk Lymphoma; 2017 May; 58(5):1144-1152. PubMed ID: 27733075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.
    Wahlin BE; Sander B; Christensson B; Kimby E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):388-97. PubMed ID: 17255259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.
    Alvaro T; Lejeune M; Salvadó MT; Lopez C; Jaén J; Bosch R; Pons LE
    J Clin Oncol; 2006 Dec; 24(34):5350-7. PubMed ID: 17135637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
    Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
    Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen.
    Milcent B; Josseaume N; Petitprez F; Riller Q; Amorim S; Loiseau P; Toubert A; Brice P; Thieblemont C; Teillaud JL; Sibéril S
    Sci Rep; 2019 Sep; 9(1):13471. PubMed ID: 31530876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.
    Yang ZZ; Grote DM; Ziesmer SC; Xiu B; Novak AJ; Ansell SM
    Blood Cancer J; 2015 Feb; 5(2):e281. PubMed ID: 25700246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical Significance of Detecting CD4
    Liu W; Zhagn GX; Shi WZ; Dong L; Liu H; Shen XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):449-454. PubMed ID: 28446291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
    Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.
    Moroch J; Copie-Bergman C; de Leval L; Plonquet A; Martin-Garcia N; Delfau-Larue MH; Molinier-Frenkel V; Belhadj K; Haioun C; Audouin J; Swerdlow SH; Marafioti T; Gaulard P
    Am J Surg Pathol; 2012 Nov; 36(11):1636-46. PubMed ID: 23073322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell levels are prognostic in mantle cell lymphoma.
    Nygren L; Wasik AM; Baumgartner-Wennerholm S; Jeppsson-Ahlberg Å; Klimkowska M; Andersson P; Buhrkuhl D; Christensson B; Kimby E; Wahlin BE; Sander B
    Clin Cancer Res; 2014 Dec; 20(23):6096-104. PubMed ID: 25294911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.
    Wahlin BE; Sundström C; Holte H; Hagberg H; Erlanson M; Nilsson-Ehle H; Lindén O; Nordström M; Ostenstad B; Geisler CH; Brown Pde N; Lehtinen T; Maisenhölder M; Tierens AM; Sander B; Christensson B; Kimby E
    Clin Cancer Res; 2011 Jun; 17(12):4136-44. PubMed ID: 21518780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells.
    Camacho FI; Bellas C; Corbacho C; Caleo A; Arranz-Sáez R; Cannata J; Menárguez J; Sánchez-Verde L; González-Camacho L; Pérez-Martín ME; Martínez-González MA; Alvaro T; Mollejo M; Ruíz-Marcellán C; Montalbán C; Piris MA
    Mod Pathol; 2011 May; 24(5):698-707. PubMed ID: 21240256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
    Braza MS; Caraux A; Rousset T; Lafaye de Micheaux S; Sicard H; Squiban P; Costes V; Klein B; Rossi JF
    J Immunol; 2010 Jan; 184(1):134-40. PubMed ID: 19949101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
    Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
    Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
    Klapper W; Hoster E; Rölver L; Schrader C; Janssen D; Tiemann M; Bernd HW; Determann O; Hansmann ML; Möller P; Feller A; Stein H; Wacker HH; Dreyling M; Unterhalt M; Hiddemann W; Ott G;
    J Clin Oncol; 2007 Aug; 25(22):3330-6. PubMed ID: 17664481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicular variant of peripheral T-cell lymphoma mimicking follicular lymphoma: a case report with a review of the Literature.
    Goto N; Tsurumi H; Sawada M; Kanemura N; Hara T; Kasahara S; Kito Y; Takada K; Sato Y; Yoshino T; Moriwaki H; Takami T
    Pathol Int; 2011 May; 61(5):326-30. PubMed ID: 21501301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.